Focus
- Volume 21
- Number 3
- July 2023
From the Guest Editor
Reviews
Publication date: 01 July 2023
Pages239–246A substantial majority of adults in the United States will experience a potentially traumatic event (PTE) in their lifetime. A considerable proportion of those individuals will go on to develop posttraumatic stress disorder (PTSD). Distinguishing between ...
https://doi.org/10.1176/appi.focus.20230001Publication date: 01 July 2023
Pages247–256Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these ...
https://doi.org/10.1176/appi.focus.20220088Publication date: 01 July 2023
Pages257–265Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition. Although several psychotherapeutic and pharmacological treatments are recommended for PTSD, many individuals do not respond to treatment or respond only partially, highlighting ...
https://doi.org/10.1176/appi.focus.20230006Publication date: 01 July 2023
Pages266–277Posttraumatic stress disorder (PTSD) is a psychiatric condition characterized by sustained symptoms, including reexperiencing, hyperarousal, avoidance, and mood alterations, following exposure to a traumatic event. Although symptom presentations in PTSD ...
https://doi.org/10.1176/appi.focus.20230007Ask the Expert
Ethics Commentary
Bibliography
Abstracts
Influential Publications
Publication date: 01 July 2023
Pages290–295This study investigated whether impairment persists after posttraumatic stress disorder (PTSD) has resolved. Traumatically injured patients (N = 1,035) were assessed during hospital admission and at 3 (85%) and 12 months (73%). Quality of life prior to ...
https://doi.org/10.1176/appi.focus.23021016Publication date: 01 July 2023
Pages296–305Objective: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine ...
https://doi.org/10.1176/appi.focus.23021014Publication date: 01 July 2023
Pages306–314Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). ...
https://doi.org/10.1176/appi.focus.23021013Publication date: 01 July 2023
Pages315–328Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (...
https://doi.org/10.1176/appi.focus.23021011Publication date: 01 July 2023
Pages329–336As psychedelic compounds gain traction in psychiatry, there is a need to consider the active mechanism to explain the effect observed in randomized clinical trials. Traditionally, biological psychiatry has asked how compounds affect the causal pathways of ...
https://doi.org/10.1176/appi.focus.23021012Past Issues
View Issues Archive
Vol. 22 | No. 4
Vol. 22 | No. 3
Vol. 22 | No. 2
